Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
CONCLUSIONS: The effectiveness of hepatitis C virus triple therapy was lower than that reported in phase III clinical trials, possibly owing to the prioritized treatment of patients with advanced liver fibrosis. The high frequency of side effects and treatment interruptions observed supported the decision of the Brazilian authorities to suspend its use when safer and more effective drugs became available in 2015. (Source: Revista da Sociedade Brasileira de Medicina Tropical)
Source: Revista da Sociedade Brasileira de Medicina Tropical - March 6, 2018 Category: Tropical Medicine Source Type: research
Quality of life in Brazilian patients with treated or untreated chronic hepatitis C.
CONCLUSIONS: Treatment can affect the subjective perception of patients regarding quality of life. Due to the complexity of the disease, each patient must be evaluated in multiple dimensions. Thus, the results may be useful for understanding the patient's perceptions during treatment, and it can also serve as a reference for care instructions.
PMID: 29267589 [PubMed - in process] (Source: Revista do Instituto de Medicina Tropical de Sao Paulo)
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - December 21, 2017 Category: Tropical Medicine Authors: Perlin CM, Ferreira VL, Borba HHL, Wiens A, Ivantes CAP, Lenzi L, Pontarolo R Tags: Rev Inst Med Trop Sao Paulo Source Type: research
Rapid and large-scale implementation of HCV treatment advances in France, 2007 –2015
The last decade was marked by major advances in HCV treatment with the introduction of first wave protease inhibitors (1st-wave PIs, telaprevir or boceprevir) in 2011 and second direct-acting antivirals (2nd-w... (Source: BMC Infectious Diseases)
Source: BMC Infectious Diseases - December 20, 2017 Category: Infectious Diseases Authors: C écile Brouard, Marjorie Boussac-Zarebska, Christine Silvain, Julien Durand, Victor de Lédinghen, Josiane Pillonel and Elisabeth Delarocque-Astagneau Tags: Research article Source Type: research
Cost Effectiveness Analysis of The Use Of Daclatasvir + Asunaprevir in The Treatment of Patients with Chronic Hepatitis C in Peru
To evaluate the cost-effectiveness of DUAL [Daclatasvir (DCV) + Asunaprevir (ASV)] and different treatment regimens [Telaprevir (TVR) or Simeprevir (SMV), both with peginterferon-alpha and ribavirin (A/R)] in patients with Hepatitis C (HCV) genotype 1b from the perspective of Social Security in Peru. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: C Sanabria, R Roman, D Montano, D Mercado, G Valenzuela, JE Caporale Source Type: research
Access to New Treatments For Chronic Hepatitis C in Four Latin American Countries
In this study, we analyze patients ’ access to new generation direct-acting antivirals in Argentina, Brazil, Colombia and Mexico. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: NT Giao Antunes, A Ribeiro, M Ascano, R Moore Source Type: research
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from The Perspective of The Brazilian Public Health System
To perform a cost-effectiveness analysis comparing the regimens peginterferon plus ribavirin (pegIFN/RBV), boceprevir (BOC) plus pegIFN/RBV, telaprevir (TVR) plus pegIFN/RBV, and no treatment for chronic hepatitis C (CHC) adopting the perspective of the Brazilian public health system. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: HH Borba, U Rochau, A Wiens, G Sroczynski, U Siebert, R Pontarolo Source Type: research
Boceprevir and Telaprevir Effectiveness and Safety in A Brazilian Cohort of Chronic Hepatitis C Genotype 1 Patients: A Multicentric Longitudinal Study
Safety and efficacy of protease inhibitors for chronic hepatitis C (CHC) treatment were showed previously, however, the Brazilian population has been poorly represented in these investigations. Therefore, this study aimed to describe the effectiveness in terms of rapid virological response (RVR) and sustained virological response (SVR) of boceprevir and telaprevir-based regimens as well as safety of these two drugs in Brazil. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: HH Borba, A Wiens, LM Steimbach, FS Tonin, ML Pedroso, E Minowa, A Piedade, O Clark, F Fernandez-Llimos, R Pontarolo Source Type: research
Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.
CONCLUSIONS: The HCV-SI effectively differentiated among treatment regimens known to vary by side effect profiles and between patients with and without treatment discontinuation due to side effects. The HCV-SI may have value as a patient-reported outcome instrument predicting the risk of HCV treatment discontinuation.
PMID: 28931406 [PubMed - in process] (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - September 20, 2017 Category: Infectious Diseases Authors: Cachay ER, Ballard C, Colwell B, Torriani F, Hicks C, Mathews WC Tags: AIDS Res Ther Source Type: research
A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System.
In conclusion, the new method is simple and quick but accurate to evaluate whether a drug will be still efficient in the forthcoming therapeutic regimen and whether drug resistance will occur after long-term treatment with drugs.
PMID: 28904942 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - September 15, 2017 Category: Research Authors: Li JR, Li WJ, Cheng JJ, Huang MH, Wu ZY, Jiang CC, Li H, Chen JH, Lv XQ, Dong B, Jiang JD, Peng ZG Tags: Biomed Res Int Source Type: research
Recent advancement of Direct-acting antiviral agents (DAAs) in Hepatitis C therapy.
Abstract
Hepatitis C virus (HCV) infection is a major health burden worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. A complete eradication of the virus is one of the most important treatment goal for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) have been approved by FDA as the direct-acting antiviral agents. A number of promising new direct-acting antiviral agents (DAAs) have ...
Source: Mini Reviews in Medicinal Chemistry - September 12, 2017 Category: Chemistry Authors: Das D, Pandya M Tags: Mini Rev Med Chem Source Type: research
Chemical genetics-based development of small molecules targeting hepatitis C virus.
Abstract
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or...
Source: Archives of Pharmacal Research - August 30, 2017 Category: Drugs & Pharmacology Authors: Jin G, Lee J, Lee K Tags: Arch Pharm Res Source Type: research
Autoantibodies against “rods and rings”-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a “real life” cohort
AbstractAutoantibodies against inosine-5 ′-monophosphate-dehydrogenase-2 (IMPDH2; “rods and rings” pattern) develop in chronic hepatitis C (CHC) patients under treatment with peg-interferon (IFN) and ribavirin (RBV), an inhibitor of IMPDH2. We investigated the influence of the alternative therapy with direct-acting antivirals (DAA)/r ibavirin on anti-IMPDH2 autoantibody generation and the use of anti-IMPDH2 development as a marker for therapy outcome (sustained virologic response, SVR). We analyzed a “real life” cohort of 104 unselected CHC genotype 1 (GT1) patients treated with IFN/first-generation DAA/RBV prosp...
Source: Medical Microbiology and Immunology - August 16, 2017 Category: Microbiology Source Type: research
Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.
In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmac...
Source: Clinical Immunology - July 20, 2017 Category: Allergy & Immunology Authors: Alessandra S, Nicola T, Federica T, Giulia R, GianMaria F, Fabiola C, Marzia M, Raffaella L, Chiara T, Gianpiero D, Rita C, Veronica B, Eleonora C, Federico M, Chiara A Tags: Clin Immunol Source Type: research
Efficacy and safety of telaprevir with natural human interferon ‐β and ribavirin in Japanese chronic hepatitis C patients with depression
ConclusionThis study showed that an addition of TVR to IFN‐β/RBV therapy raised SVR in previously treated and untreated genotype 1 patients and previously treated genotype 2 patients with chronic hepatitis C and depression. (Source: Hepatology Research)
Source: Hepatology Research - July 19, 2017 Category: Internal Medicine Authors: Hiromitsu Kumada, Satoshi Mochida, Makoto Nakamuta, Fumitaka Suzuki, Takashi Yagi, Ryuji Takasaki, Masao Okai, Naohiro Kamiya, Yasushi Okada, Saya Hirota, Madori Orihashi, Miyoko Ochi, Kazuaki Chayama Tags: Original Article Source Type: research
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
CONCLUSION: Although serious adverse events rates were higher in this infected population, sustained viral response rates were similar to those reported for other patient cohorts. (Source: Clinics)
Source: Clinics - June 23, 2017 Category: General Medicine Source Type: research
